ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma's stock surges as anticipation builds for Phase [--] FURVENT trial results and inclusion in a key biotech catalyst watchlist. The company is experiencing a significant spike in social media mentions and engagements.
About ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. is a biopharmaceutical company focused on developing novel therapeutics.
ArriVent BioPharma, Inc. uses the ticker $AVBP for trading. Listed in the Stocks category.
Insights
- ArriVent BioPharma, Inc. (AVBP) mentions hit [---] which is 492% higher than it's daily average.
- ArriVent BioPharma, Inc. (AVBP) engagements hit 12.9K which is 473% higher than it's daily average.
- ArriVent BioPharma, Inc. (AVBP) social dominance hit [------] which is 383% higher than it's daily average.
- ArriVent BioPharma, Inc. (AVBP) social dominance is up 1985.71% from the previous [--] months.
- ArriVent BioPharma, Inc. (AVBP) creators is up 13.48% from the previous week.
- ArriVent BioPharma, Inc. (AVBP) engagements is up 79.72% from the previous week.
- ArriVent BioPharma, Inc. (AVBP) mentions is up 29.29% from the previous week.
- ArriVent BioPharma, Inc. (AVBP) posts created is up 109.14% from the previous [--] months.
Price: $22.50
Price 24-Hour Time-Series Raw Data
The stock price has reached a 52-week and all-time high, strongly correlated with the anticipation of upcoming clinical trial readouts, particularly the Phase [--] FURVENT trial, and its inclusion in a biotech catalyst watchlist, alongside a significant surge in social media mentions and engagements.
24-Hour: -1.88% 7-Day: 6.45% 30-Day: 7.67%
1-Year High: $25.40 on 2025-06-16
1-Year Low: $17 on 2025-08-12
AltRank: [---]
AltRank 24-Hour Time-Series Raw Data
ArriVent BioPharma, Inc. (AVBP) is currently AltRank #713 based on combined combined social and market metrics
Daily Average: [-----]
[--] Week: [---] [----]
1-Year High: [-----] on 2026-02-11
1-Year Low: [---] on 2026-01-25
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] +35
[--] Months: [--] +29
[--] Year: [--] +8
1-Year High: [--] on 2026-02-08
1-Year Low: [--] on 2025-10-25
Engagements: [------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [-----]
[--] Week: [------] +80%
[--] Month: [-------] -4.20%
[--] Months: [-------] +141%
[--] Year: [-------] +164%
1-Year High: [------] on 2025-06-23
1-Year Low: [--] on 2025-06-02
Engagements by network (24h): X: [------] Reddit: [--] YouTube: [--] News: [--]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [--]
[--] Week: [---] +29%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-06-02
Mentions by network (24h): X: [---] Reddit: [--] YouTube: [--] News: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning ArriVent BioPharma, Inc. (AVBP) in the last [--] hours which is down 5.60% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [---] +13%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-06-02
The most influential creators that mention ArriVent BioPharma, Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @BiopharmIQ | [--] | [------] | [--] | [------] |
| @RiskInhibitor | [--] | [--] | [--] | [-----] |
| @dagoonglove | [--] | [-----] | [--] | [---] |
| @grok | [--] | [---------] | [--] | [---] |
| @DudeBiotech | [--] | [-----] | [--] | [---] |
| @B71042204Ashley | [--] | [--] | [--] | [---] |
| @WrightWhit84274 | [--] | [--] | [--] | [--] |
| @SandraG62844642 | [--] | [---] | [--] | [--] |
| @JolieRosy96450 | [--] | [--] | [--] | [--] |
| @FPopeos92355 | [--] | [--] | [--] | [--] |
Sentiment: 86%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 86%
Daily Average: 70%
[--] Week: 50% -17%
[--] Month: 78% +28%
[--] Months: 78% -22%
[--] Year: 78% +11%
1-Year High: 100% on 2025-02-19
1-Year Low: 12% on 2025-10-10
Most Supportive Themes:
- Biotech Stock Catalyst Watchlist: (92%) Upcoming Phase [--] and Phase [--] clinical trial readouts for various biotech stocks in Q1 2026, including $AVBP.
Most Critical Themes:
Social Dominance: 0.01%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.01%
Daily Average: 0.00302%
[--] Week: 0.025% +0.022%
[--] Month: 0.015% +0.013%
[--] Months: 0.015% +0.013%
[--] Year: 0.015% +0.012%
1-Year High: 0.031% on 2025-06-29
1-Year Low: 0.0001% on 2025-10-15
Market Dominance: 0.00105%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00105%
Daily Average: 0%
1-Year High: 0.0012% on 2026-01-22
1-Year Low: 0.001% on 2026-01-16
Market Cap: $927,179,368
Market Cap 24-Hour Time-Series Raw Data
Current Value: $927,179,368
Daily Average: $919,548,214
[--] Week: $939,150,963 +6.40%
[--] Month: $927,179,368 +7.70%
1-Year High: $1,040,290,297 on 2026-01-22
1-Year Low: $861,129,190 on 2026-01-16
Top ArriVent BioPharma, Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"Aura Biosciences (2021 IPO): Priced at $14. First day close: $13.50 (down 3.6%). Amylyx Pharmaceuticals (2022 IPO): Priced at $19. First day close: $18.07 (down 4.9%). Abivax (2023 IPO): Priced at $11.60. First day close: $8.30 (down 28%). ArriVent BioPharma (2024 IPO): Priced at $18. First day close: $20 (up 11%). Note: IPOs have no pre-trading prices; these show offering vs. first close. Reactions vary by market. (348 chars) https://twitter.com/i/web/status/2023224651720106354 https://twitter.com/i/web/status/2023224651720106354"
X Link @grok 2026-02-16T02:35Z 8M followers, [---] engagements
"After $GOSS short I will be full port $AVBP through readout"
X Link @RiskInhibitor 2026-02-16T01:03Z [--] followers, [----] engagements
"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $BIVI Phase [--] $MDNAF Phase 2b $DBVT Phase [--] $GOSS Phase [--] $MLTX Phase [--] $BFRI Phase [--] $BCDA Phase [--] $KPTI Phase [--] $IOVA Phase [--] $XENE Phase [--] $AGIO Phase 2b $AVBP Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $IDYA Phase 2/3 $VXRT Phase 2b $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $ALZN Phase [--] $HELP Phase [--] $PVLA Phase [--] $INSM"
X Link @BiopharmIQ 2026-02-15T19:38Z 28.9K followers, [----] engagements
"🧬 Biopharma Weekly Recap 📝 This week in biotech: $NKTR AtD data and financing ignite upside debate GLP-1 pill surge boosts $NVO/$LLY M&A chatter builds and dense Q1 readouts drive volatility. See interesting posts/ppl to check out 👇 @AppleHelix 1/ There is some confusion with the reporting on $MRNA Refuse to File. @seedy19tron The Weekly 🌱 New: $anl $tern $cmps Increased: $abvx $nktr Unchanged: $nxtc $ovid $slno $cntx $pasg $dawn $lqda $rytm Decreased: Closed: $crvs (s) $apge (s) $asnd $ptn $cogt @Andre_AGTC My watch list near term catalysts @ResearchPulse1 Can UBT251 from NVO be a"
X Link @BiopharmIQ 2026-02-14T16:03Z 28.9K followers, 11.5K engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing